generic makers Deal History & Licensing Activity
generic makers is a life sciences. Over the past three years, generic makers has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Small Molecules
Focus Area
Infectious Disease
generic makers Recent Deal Activity
Licensing, acquisition, and partnership transactions involving generic makers in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| lenacapavir | Gilead Sciences | Small Molecules | Unknown | license | Apr 2026 |
generic makers Pipeline Focus
Therapeutic areas and modalities where generic makers is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches generic makers's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About generic makers Licensing & Deal Activity
generic makers is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, generic makers ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for generic makers include Infectious Disease (2 deals and trials). In terms of modality, generic makers has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for generic makers and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against generic makers's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.